Biotech Industry’s Stocks Get Research Review

LONDON, UK / ACCESSWIRE / June 3, 2016 / ActiveWallSt.com announces the list of stocks for today’s research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Biotechnology industry. Companies recently under review include XOMA, Vericel, Cara Therapeutics, and Regulus Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:

http://www.activewallst.com/register/

Today, ActiveWallSt.com is promoting its equity research coverage. Get all of our research report free by signing up to http://www.activewallst.com/register/.

There are a number of uncertainties enveloping the Biotech industry at present and these include pricing issues and volatility which are putting even more strain on stocks in this space. Investors, nonetheless, believe that the Biotech segment is close to rebounding. Let us take a look at how each of the companies mentioned above have performed over the last few trading sessions. Access the free reports on these stocks by clicking below:
http://www.activewallst.com/register/.

XOMA Corp. (NASDAQ: XOMA)

Shares in California-based development stage biotechnology Company, XOMA Corp., ended Thursday’s session at $0.69, gaining 2.11%. The stock recorded a trading volume of 581,059 shares. The Company’s shares are trading 10.78% below their 50-day moving average. Moreover, shares of XOMA have a Relative Strength Index (RSI) of 42.85.

Vericel Corp. (NASDAQ: VCEL)

Cambridge, Massachusetts headquartered commercial-stage biopharmaceutical Company, Vericel Corp.’s stock closed the day flat at $2.82 with a total volume of 82,795 shares traded. The Company’s shares have advanced 45.36% in the previous three months and 9.30% since the start of this year. The stock is trading 2.93% above its 200-day moving average. Additionally, shares of Vericel have an RSI of 40.85.

Cara Therapeutics Inc. (NASDAQ: CARA)

On Thursday, shares in Shelton, Connecticut based a clinical-stage biopharmaceutical Company, Cara Therapeutics Inc., recorded a trading volume of 738,487 shares. The stock ended the day 5.05% higher at $6.45. The Company’s shares have advanced 5.22% in the past month and 14.36% in the previous three months. The stock is trading above its 50-day moving average by 1.87%. Furthermore, shares of Cara Therapeutics have an RSI of 57.00.

Regulus Therapeutics Inc. (NASDAQ: RGLS)

Regulus Therapeutics Inc. is a biopharmaceutical Company that focuses on the discovery and development of drugs that target RNAs to treat a variety of diseases in the U.S. The Company’s stock climbed 4.03%, finishing yesterday’s session at $6.20 and with a total volume of 709,136 shares traded. The Company’s shares have advanced 13.97% in the last one month. The stock is trading below its 50-day moving average by 2.88%. Additionally, shares of Regulus Therapeutics have an RSI of 53.89.

—
Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number:  1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 440723